2019冠状病毒病大流行对启动生物疾病改善抗风湿药物的首个影响：来自TReasure真实世界数据库的结果
The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database.
作者信息
Alpay Kanıtez Nilüfer, Kiraz Sedat, Dalkılıç Ediz, Kimyon Gezmiş, Mercan Rıdvan, Karadağ Ömer, Bes Cemal, Kılıç Levent, Akar Servet, Ateş Aşkın, Emmungil Hakan, Ertenli İhsan, Pehlivan Yavuz, Coşkun Belkıs Nihan, Yağız Burcu, Ersözlü Duygu, Gönüllü Emel, Çınar Muhammet, Kaşifoğlu Timuçin, Koca Süleyman Serdar, Karasu Uğur, Küçükşahin Orhan, Kalyoncu Umut
机构信息
Division of Rheumatology, Department of Internal Medicine, Koç University School of Medicine, İstanbul, Turkey.
Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
出版信息
Eur J Rheumatol. 2022 Oct;9(4):206-211. doi: 10.5152/eurjrheum.2022.21153.
OBJECTIVE
The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis.
METHODS
Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months).
RESULTS
The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period.
CONCLUSION
The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.
目的
2019年冠状病毒病大流行导致医院占用率上升。风湿性疾病患者仍无法前往医院，或者即使能够前往医院，他们也会对就医犹豫不决。我们旨在展示2019年冠状病毒病大流行第一波对类风湿关节炎或脊柱关节炎患者使用生物疾病改善抗风湿药物治疗的影响。
方法
患者分为以下三组：疫情前（Pre-p：在2020年3月11日前6个月内首次开始使用生物疾病改善抗风湿药物治疗）；疫情后A组（Post-p A：在2020年3月11日后的前6个月内首次开始使用生物疾病改善抗风湿药物治疗）；疫情后B组（Post-p B：在第二个6个月内首次开始使用生物疾病改善抗风湿药物治疗）。
结果
与Pre-p组相比，Post-p A组和B组类风湿关节炎患者数量分别减少了51%和48%，脊柱关节炎患者数量也出现了类似的减少率。在疫情后时期，类风湿关节炎患者使用托法替布和阿巴西普的比例有所增加。
结论
在2019年冠状病毒病大流行的第一年，首次开始使用生物疾病改善抗风湿药物的类风湿关节炎和脊柱关节炎患者数量有所减少。
Zotero 插件